Home » ACTAVIS RECEIVES WARNING FROM FDA
ACTAVIS RECEIVES WARNING FROM FDA
Icelandic generic pharmaceuticals company Actavis said that it has received a warning letter from the FDA relating to the company's solid oral dose manufacturing facility in New Jersey, US. Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=AEE1D6E6-EB09-4925-9F7B-080B8F31EAC2)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct